GLIOBLASTOMA MULTIFORME (ADULT BRAIN CANCER)

Diffuse Midline Glioma; GBM; Giant Cell Glioblastoma; Glioblastoma; Glioblastoma Adult Brain Tumor; Glioblastoma, IDH Mutant; Glioblastoma, IDH Wildtype; Glioblastoma, NOS; Gliosarcoma; Gliosarcoma, IDH Wildtype; Grade IV Astrocytoma; H3K27M-Mutant

Glioblastoma multiforme is a fast-growing type of central nervous system cancer that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. It spreads aggressively throughout the brain tissue and is the most malignant of the primary brain cancers. In consequence, these cancers are difficult to treat and often recur after initial therapy. Glioblastoma multiforme most often occurs in adults between the ages of 45 and 70 years and affects the brain more often than the spinal cord.

Diagnostic testing: Diagnosis is based on:

• •

  Patient history;

• •

  Neurological examination; and

• •

  Diagnostic procedures.

The only definitive test that can provide a diagnosis of glioblastoma is a biopsy of the cancer. Testing to confirm diagnosis of glioblastoma includes neuroimaging (computed tomography (CT) and magnetic resonance imaging (MRI)) to provide information about the location, size, and shape of the cancer.

Physical findings: Individuals with this impairment may present with:

• •

  Slowly progressive neurologic deficits;

• •

  Motor weakness;

• •

  Increased intracranial pressure including headaches, nausea, and vomiting, and cognitive impairments;

• •

  Changes in mood and personality; and

• •

  Seizures.

ICD-9: 191.9

ICD-10: C71.9

Glioblastoma multiforme is highly aggressive, infiltrating, and responds poorly to all currently available treatments. The prognosis is grim, as most patients die within two years and few survive longer than three years.

Treatment of glioblastoma multiforme may include the following: surgery, radiation, and/or chemotherapy.

Suggested Listings for Evaluation:

• •

  Pathology report of the cancer biopsy or surgical specimen is the critical information necessary for disability evaluation;

• •

  Clinical history and examination that describes the diagnostic features of the impairment;

• •

  Pathology reports;

• •

  Operative reports; and

• •

  Results of neuroimaging (e.g. CT scan, MRI scan).

Suggested Listings for Evaluation:

REMARKS